AR111983A1 - ANILLOS 6 - 5 FUSIONADOS COMO INHIBIDORES DE C5a - Google Patents

ANILLOS 6 - 5 FUSIONADOS COMO INHIBIDORES DE C5a

Info

Publication number
AR111983A1
AR111983A1 ARP180101449A ARP180101449A AR111983A1 AR 111983 A1 AR111983 A1 AR 111983A1 AR P180101449 A ARP180101449 A AR P180101449A AR P180101449 A ARP180101449 A AR P180101449A AR 111983 A1 AR111983 A1 AR 111983A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
haloalkyl
independently selected
ring
Prior art date
Application number
ARP180101449A
Other languages
English (en)
Spanish (es)
Inventor
Penglie Zhang
Yibin Zeng
Hiroko Tanaka
Rajinder Singh
Sreenivas Punna
Venkat Reddy Mali
Viengkham Malathong
Rebecca M Lui
Christopher W Lange
Pingchen Fan
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of AR111983A1 publication Critical patent/AR111983A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Liquid Crystal Substances (AREA)
  • Glass Compositions (AREA)
ARP180101449A 2017-05-31 2018-05-31 ANILLOS 6 - 5 FUSIONADOS COMO INHIBIDORES DE C5a AR111983A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762513010P 2017-05-31 2017-05-31

Publications (1)

Publication Number Publication Date
AR111983A1 true AR111983A1 (es) 2019-09-11

Family

ID=64456009

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180101449A AR111983A1 (es) 2017-05-31 2018-05-31 ANILLOS 6 - 5 FUSIONADOS COMO INHIBIDORES DE C5a

Country Status (14)

Country Link
US (3) US10562896B2 (enExample)
EP (1) EP3630775B1 (enExample)
JP (1) JP7141130B2 (enExample)
KR (1) KR102638253B1 (enExample)
CN (1) CN110997674B (enExample)
AR (1) AR111983A1 (enExample)
AU (1) AU2018277520B2 (enExample)
IL (1) IL270828B2 (enExample)
MA (1) MA48803A (enExample)
MX (1) MX392259B (enExample)
NZ (1) NZ759297A (enExample)
TW (1) TWI781177B (enExample)
WO (1) WO2018222598A1 (enExample)
ZA (1) ZA201907746B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ759297A (en) 2017-05-31 2026-03-27 Chemocentryx Inc 6-5 fused rings as c5a inhibitors
KR102586710B1 (ko) 2017-05-31 2023-10-10 케모센트릭스, 인크. C5a 억제제로서의 5-5 융합 고리
CN111788184B (zh) 2017-12-22 2023-12-22 凯莫森特里克斯股份有限公司 用作C5aR抑制剂的二芳基取代的5,5-稠合环化合物
WO2019126424A1 (en) * 2017-12-22 2019-06-27 Chemocentryx, Inc. DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS
ES2993034T3 (en) * 2018-04-02 2024-12-20 Chemocentryx Inc Prodrugs of fused-bicyclic c5ar antagonists
US11872217B2 (en) 2019-07-10 2024-01-16 Chemocentryx, Inc. Indanes as PD-L1 inhibitors
CN112625036A (zh) * 2019-10-08 2021-04-09 上海海和药物研究开发股份有限公司 一类具有brd4抑制活性的化合物、其制备方法及用途
US11713307B2 (en) 2019-10-16 2023-08-01 Chemocentryx, Inc. Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases
CR20220216A (es) 2019-10-16 2023-01-09 Chemocentryx Inc Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
WO2022013684A1 (en) 2020-07-11 2022-01-20 Pfizer Inc. Antiviral heteroaryl ketone derivatives
US20220047592A1 (en) * 2020-08-13 2022-02-17 Chemocentryx, Inc. METHODS OF TREATING RESPIRATORY DISEASES USING C5a INHIBITORS
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
MX2023004801A (es) 2020-10-28 2023-05-10 Chemocentryx Inc Metodos de tratamiento de hidradenitis supurativa.
CN112979646B (zh) * 2021-03-08 2022-01-14 北京富龙康泰生物技术有限公司 一种咪唑并吡啶类衍生物

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK27383A (da) 1982-02-17 1983-08-18 Lepetit Spa Fremgangsmaade til fremstilling af pyrazol(4,3-c)pyridiner
GB8613591D0 (en) 1986-06-04 1986-07-09 Roussel Lab Ltd Chemical compounds
FR2761266B1 (fr) 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
JP4555547B2 (ja) 2000-08-10 2010-10-06 ファイザー イタリア ソシエタ ア レスポンサビリタ リミタータ キナーゼ阻害剤としての二環式ピラゾール、それらを製造するための方法およびそれらを含む医薬組成物
DE60039921D1 (de) 2000-09-29 2008-09-25 Neurogen Corp Hochaffine kleinmolekülige c5a-rezeptor-modulatoren
SE524438C2 (sv) 2000-10-05 2004-08-10 Magnus Georg Goertz Fjärrstyrt dörrelaterat låsarrangemang, första och andra datorpogramprodukt, bärande medium och ett datorlösbart medium
JP4196678B2 (ja) * 2001-04-26 2008-12-17 味の素株式会社 複素環化合物
ITMI20012025A1 (it) 2001-09-28 2003-03-28 Dompe Spa Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono
AU2003225971A1 (en) 2002-03-28 2003-10-13 Yang Gao Substituted biaryl amides as c5a receptor modulators
WO2003082828A1 (en) 2002-03-28 2003-10-09 Neurogen Corporation Substituted tetrahydroisoquinolines as c5a receptor modulators
JP2005530719A (ja) 2002-03-29 2005-10-13 ニューロジェン コーポレーション 病原性炎症要素を有する状態の治療のための組み合わせ療法
AU2003265395A1 (en) * 2002-08-14 2004-03-03 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
US7169775B2 (en) 2002-08-21 2007-01-30 Neurogen Corporation Amino methyl imidazoles as C5a receptor modulators
ATE552253T1 (de) 2002-11-08 2012-04-15 Novartis Int Pharm Ltd 3-substituierte-6-aryl- pyridin derivate als liganden für c5a-rezeptoren
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US20040214856A1 (en) 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
AU2003902354A0 (en) 2003-05-15 2003-05-29 Harkin, Denis W. Treatment of haemorrhagic shock
WO2005007087A2 (en) 2003-07-03 2005-01-27 Neurogen Corporation Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators
US7906528B2 (en) 2004-10-05 2011-03-15 Novartis International Pharmaceutical Ltd. Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
BRPI0614397A2 (pt) 2005-08-04 2011-03-29 Janssen Pharmaceutica Nv compostos de pirimidina como moduladores de receptor de serotonina
US20070112015A1 (en) 2005-10-28 2007-05-17 Chemocentryx, Inc. Substituted dihydropyridines and methods of use
WO2008024978A2 (en) 2006-08-24 2008-02-28 Serenex, Inc. Tetrahydroindolone and tetrahydroindazolone derivatives
US20100035875A1 (en) 2008-06-20 2010-02-11 Bing-Yan Zhu Triazolopyridine jak inhibitor compounds and methods
SMT202200074T1 (it) 2008-12-22 2022-03-21 Chemocentryx Inc Antagonisti di c5ar
US20110275639A1 (en) 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
BR112012004335A8 (pt) 2009-09-02 2016-06-21 Merck Sharp & Dohme Composto, composição farmacêutica, e, uso do composto.
HRP20171176T1 (hr) 2010-06-24 2017-10-06 Chemocentryx, Inc. C5ar antagonisti
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
JP6250674B2 (ja) 2012-08-16 2017-12-20 ヤンセン ファーマシューティカ エヌ.ベー. N型カルシウムチャネル遮断剤としてのピロロピラゾール
CN103421006B (zh) * 2013-08-18 2016-06-22 上海师范大学 2,3,5,7-四取代二氢吡唑并六氢吡啶衍生物及其制备方法和应用
GB201321746D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
WO2017176620A2 (en) * 2016-04-04 2017-10-12 Chemocentryx, Inc. SOLUBLE C5aR ANTAGONISTS
NZ759297A (en) 2017-05-31 2026-03-27 Chemocentryx Inc 6-5 fused rings as c5a inhibitors
KR102586710B1 (ko) 2017-05-31 2023-10-10 케모센트릭스, 인크. C5a 억제제로서의 5-5 융합 고리
US10589871B2 (en) 2017-09-25 2020-03-17 Hamilton Sundstrand Corporation Prognostic health monitoring and jam detection for use with an aircraft
CN111788184B (zh) 2017-12-22 2023-12-22 凯莫森特里克斯股份有限公司 用作C5aR抑制剂的二芳基取代的5,5-稠合环化合物
WO2019126424A1 (en) 2017-12-22 2019-06-27 Chemocentryx, Inc. DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS
ES2993034T3 (en) 2018-04-02 2024-12-20 Chemocentryx Inc Prodrugs of fused-bicyclic c5ar antagonists

Also Published As

Publication number Publication date
MA48803A (fr) 2020-04-08
US20200347049A1 (en) 2020-11-05
BR112019025049A2 (pt) 2020-06-16
AU2018277520A1 (en) 2019-12-12
MX392259B (es) 2025-03-24
WO2018222598A1 (en) 2018-12-06
JP2020522484A (ja) 2020-07-30
US10562896B2 (en) 2020-02-18
JP7141130B2 (ja) 2022-09-22
EP3630775A1 (en) 2020-04-08
KR20200015604A (ko) 2020-02-12
TWI781177B (zh) 2022-10-21
US11384079B2 (en) 2022-07-12
NZ759297A (en) 2026-03-27
ZA201907746B (en) 2023-10-25
EP3630775B1 (en) 2022-12-14
CN110997674B (zh) 2022-12-20
IL270828B (en) 2022-12-01
EP3630775A4 (en) 2020-10-07
KR102638253B1 (ko) 2024-02-16
US20180370967A1 (en) 2018-12-27
CA3064017A1 (en) 2018-12-06
TW201902895A (zh) 2019-01-16
RU2019142942A (ru) 2021-06-30
CN110997674A (zh) 2020-04-10
IL270828B2 (en) 2023-04-01
RU2019142942A3 (enExample) 2021-09-03
AU2018277520B2 (en) 2022-03-17
US11773091B2 (en) 2023-10-03
IL270828A (en) 2020-01-30
US20230151002A1 (en) 2023-05-18

Similar Documents

Publication Publication Date Title
AR111841A1 (es) ANILLOS 5-5 FUSIONADOS COMO INHIBIDORES DE C5a
AR106605A1 (es) Oxadiazoles sustituidos para combatir hongos fitopatógenos
CR20160548A (es) Nuevos Derivados de Pirazolo Pirimidina y su Uso como Inhibidores de MALT1
AR088565A1 (es) Inhibidor de cetp de oxazolidinona biciclico fusionado
AR094557A1 (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con deficiencia de smn
AR096788A1 (es) Compuestos tricíclicos de carboxamida como inhibidores potentes de rock
AR099228A1 (es) Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos
AR095311A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
AR100033A1 (es) Compuestos y composiciones para inhibir la actividad de shp2
AR094550A1 (es) Inhibidores de btk
AR102948A1 (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo como inhibidores del receptor p2x3
AR088175A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen
CR20170118A (es) Derivados espirodiamina como inhibidores de la aldosterona sintasa
AR120246A1 (es) Aminas heteroaril-bifenilas para el tratamiento de las enfermedades por pd-l1
AR100776A1 (es) Compuestos herbicidas
AR102258A1 (es) Compuestos de quinolina y quinazolina
AR103266A1 (es) Compuestos cíclicos sustituidos con un sistema de anillos condensado para combatir plagas de invertebrados
AR102544A1 (es) Compuestos derivados de dihidrohidantoína como herbicidas
AR095059A1 (es) Compuestos herbicidas
MX2015016400A (es) Nuevos compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona.
AR093801A1 (es) Derivados de 1,4-ditiina sustituida y su uso como fungicidas
AR099867A1 (es) Compuestos imidazobenzotiazolo fusionados
AR091534A1 (es) Derivados de sulfonamida y metodos de uso de los mismos para mejorar la farmacocinetica de un farmaco
AR096552A1 (es) Compuesto de amida heterocíclica aromática que contiene nitrógeno bicíclico
AR109387A1 (es) INHIBIDORES DEL FACTOR XIa